

3rd April 2025

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001 BSE – AJANTPHARM 532331	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 NSE AJANTPHARM EQ	Audit Committee Ajanta Pharma Limited
--	--	--

Re: Disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir/ Madam,

Pursuant to provisions of Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, I hereby declare on behalf of promoters & promoter group of Ajanta Pharma Ltd. that we have not made any encumbrance, directly or indirectly, other than those already disclosed during the financial year ended 31st March 2025.

Thanking you,
Yours faithfully,

YOGESH MANNALAL AGRAWAL
Digitally signed by
YOGESH MANNALAL
AGRAWAL
Date: 2025.04.03
14:21:28 +05'30'

YOGESH M. AGRAWAL

C.C. : The Company Secretary
Ajanta Pharma Limited
“Ajanta House”,
Charkop, Kandivli (West)
Mumbai – 400 067